Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Judith M. Müller(The Netherlands Cancer Institute), Oscar Krijgsman(The Netherlands Cancer Institute), Jennifer Tsoi(University of California, Los Angeles), Lídia Robert(University of California, Los Angeles), Willy Hugo(University of California, Los Angeles), Chunying Song(University of California, Los Angeles), Xiangju Kong(University of California, Los Angeles), Patrícia A. Possik(The Netherlands Cancer Institute), Paulien Cornelissen‐Steijger(The Netherlands Cancer Institute), Marnix H. Geukes Foppen(The Netherlands Cancer Institute), Kristel Kemper(The Netherlands Cancer Institute), Colin R. Goding(Ludwig Cancer Research), Ultan McDermott(Wellcome Sanger Institute), Christian U. Blank(The Netherlands Cancer Institute), John B.A.G. Haanen(The Netherlands Cancer Institute), Thomas G. Graeber(California NanoSystems Institute), Antoni Ribas(University of California, Los Angeles), Roger S. Lo(University of California, Los Angeles), Daniel S. Peeper(The Netherlands Cancer Institute)
Nature Communications
December 15, 2014
10.1038/ncomms6712
Cited by 633Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis